MEI Pharma

NewsRoom

Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015

2014201320122011201020092008

Jun 7, 2021
- New Marginal Zone Arm of TIDAL Study Intended to Support Accelerated Approval Application with the U.S. Food and Drug Administration -
Jun 4, 2021
-- Event Scheduled for Thursday, June 10, 2021 at 12:00 PM Eastern Time Featuring Deepa Jagadeesh, M.D. --
May 19, 2021
-Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) who had progression of disease within 24 months of first line chemoimmunotherapy (POD24); overall response rate of 93% in non-POD24-
May 6, 2021
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
Apr 10, 2021
Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021
Feb 4, 2021
--Multiple Clinical Development Milestones Anticipated in 2021--
 

https://investor.meipharma.com/news?pagetemplate=printable